Most cancers develop over many years as cellular damage gradually accumulates, with only a small percentage resulting from inherited genetic mutations passed down through families. Identifying these inherited mutations is crucial because healthy relatives can undergo testing long before any signs of cancer appear. This early detection enables physicians to implement earlier screening measures and, in some cases, take preventive steps against life-threatening illnesses.
A recent study has revealed a previously unrecognized inherited factor linked to aggressive prostate cancer. Researchers from the University of British Columbia, along with international partners, found that rare inherited mutations in a gene called CDK12 may significantly increase risk for certain families. The team analyzed DNA from over 4,500 men diagnosed with aggressive prostate cancer. They discovered five unrelated men from different families who carried inherited CDK12 mutations. All were diagnosed with metastatic prostate cancer between ages 44 and 62, indicating that the disease had already spread at the time of diagnosis.
For many years, scientists believed that mutations in CDK12 were random and occurred only within tumors. However, by closely examining the genetic makeup of these patients’ cancers, researchers identified a specific genetic signature showing that inherited mutations in CDK12 disable the gene’s normal function and directly contribute to cancer development.
This discovery has the potential to change how doctors approach screening and prevention in families at risk. Although mutations in CDK12 are rare, testing relatives of affected individuals could identify those who need more vigilant and earlier prostate cancer screening. Detecting cancer before it metastasizes greatly enhances treatment success rates.
The study also observed that several families with CDK12 mutations had relatives who had ovarian cancer, and one patient with ovarian cancer was found to carry the same genetic mutation. While more research is necessary, these findings suggest that CDK12 mutations might influence the risk of multiple types of cancer.
Since testing for CDK12 mutations can be performed with current genetic screening methods, this discovery is likely to be integrated into routine medical practice sooner rather than later, offering high-risk families critical insights into their future health. The research was published in the journal Cancer Discovery.
While this genetic change is extremely rare and unlikely to account for most prostate cancer cases, its importance for affected families could be immense. Early genetic screening can facilitate detection before the cancer spreads, significantly improving treatment outcomes. The study’s findings are supported by comprehensive genetic analysis of tumor samples, adding credibility to the results.
Further research is needed to determine the prevalence of these mutations and whether they increase susceptibility to other cancers, but the ability to detect CDK12 mutations with existing tests means these findings could quickly influence clinical care.
For those interested in cancer risk factors, recent studies have linked artificial sweeteners to increased cancer risk and explored how milk consumption impacts heart disease and cancer. Additional research on the optimal timing for vitamin intake to prevent heart disease and the benefits of vitamin D supplements in reducing cancer mortality is also available.
